Scientists are rapidly investigating retatrutide, a novel medication from Eli Lilly, as a potential step in body reduction . Distinct from many existing approaches, retatrutide is a twin-action agonist targeting simultaneously GLP-1 and GIP, chemicals that affect hunger and glucose regulation . Pre